These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 29174525)
1. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. De Sanctis R; Pane M; Coratti G; Palermo C; Leone D; Pera MC; Abiusi E; Fiori S; Forcina N; Fanelli L; Lucibello S; Mazzone ES; Tiziano FD; Mercuri E Neuromuscul Disord; 2018 Jan; 28(1):24-28. PubMed ID: 29174525 [TBL] [Abstract][Full Text] [Related]
2. Longitudinal natural history of type I spinal muscular atrophy: a critical review. Mercuri E; Lucibello S; Perulli M; Coratti G; de Sanctis R; Pera MC; Pane M; Montes J; de Vivo DC; Darras BT; Kolb SJ; Finkel RS Orphanet J Rare Dis; 2020 Apr; 15(1):84. PubMed ID: 32248834 [TBL] [Abstract][Full Text] [Related]
3. Association between the SMN2 gene copy number and clinical characteristics of patients with spinal muscular atrophy with homozygous deletion of exon 7 of the SMN1 gene. Zarkov M; Stojadinović A; Sekulić S; Barjaktarović I; Perić S; Keković G; Drasković B; Stević Z Vojnosanit Pregl; 2015 Oct; 72(10):859-63. PubMed ID: 26665550 [TBL] [Abstract][Full Text] [Related]
4. Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data. Pane M; Coratti G; Sansone VA; Messina S; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Bravetti C; Berti B; Brigati G; Tacchetti P; Salmin F; de Sanctis R; Lucibello S; Piastra M; Genovese O; Bertini E; Vita G; Tiziano FD; Mercuri E; Ann Neurol; 2019 Sep; 86(3):443-451. PubMed ID: 31228281 [TBL] [Abstract][Full Text] [Related]
5. An observational study of functional abilities in infants, children, and adults with type 1 SMA. Pane M; Palermo C; Messina S; Sansone VA; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Brigati G; de Sanctis R; Coratti G; Lucibello S; Bertini E; Vita G; Danilo Tiziano F; Mercuri E; Neurology; 2018 Aug; 91(8):e696-e703. PubMed ID: 30045959 [TBL] [Abstract][Full Text] [Related]
7. Validation of the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Glanzman AM; McDermott MP; Montes J; Martens WB; Flickinger J; Riley S; Quigley J; Dunaway S; O'Hagen J; Deng L; Chung WK; Tawil R; Darras BT; Yang M; Sproule D; De Vivo DC; Kaufmann P; Finkel RS; ; Pediatr Phys Ther; 2011; 23(4):322-6. PubMed ID: 22090068 [TBL] [Abstract][Full Text] [Related]
8. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study. Aragon-Gawinska K; Seferian AM; Daron A; Gargaun E; Vuillerot C; Cances C; Ropars J; Chouchane M; Cuppen I; Hughes I; Illingworth M; Marini-Bettolo C; Rambaud J; Taytard J; Annoussamy M; Scoto M; Gidaro T; Servais L Neurology; 2018 Oct; 91(14):e1312-e1318. PubMed ID: 30158155 [TBL] [Abstract][Full Text] [Related]
9. Genotype-phenotype correlation of SMN locus genes in spinal muscular atrophy children from Argentina. Medrano S; Monges S; Gravina LP; Alías L; Mozzoni J; Aráoz HV; Bernal S; Moresco A; Chertkoff L; Tizzano E Eur J Paediatr Neurol; 2016 Nov; 20(6):910-917. PubMed ID: 27510309 [TBL] [Abstract][Full Text] [Related]
10. Type I SMA "new natural history": long-term data in nusinersen-treated patients. Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Brigati G; Tacchetti P; Salmin F; De Sanctis R; Lucibello S; Pera MC; Piastra M; Genovese O; Bertini E; Vita G; Tiziano FD; Mercuri E; Ann Clin Transl Neurol; 2021 Mar; 8(3):548-557. PubMed ID: 33547876 [TBL] [Abstract][Full Text] [Related]
11. Association between SMN2 methylation and disease severity in Chinese children with spinal muscular atrophy. Cao YY; Qu YJ; He SX; Li Y; Bai JL; Jin YW; Wang H; Song F J Zhejiang Univ Sci B; 2016 Jan; 17(1):76-82. PubMed ID: 26739529 [TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Rudnik-Schöneborn S; Berg C; Zerres K; Betzler C; Grimm T; Eggermann T; Eggermann K; Wirth R; Wirth B; Heller R Clin Genet; 2009 Aug; 76(2):168-78. PubMed ID: 19780763 [TBL] [Abstract][Full Text] [Related]
13. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238 [TBL] [Abstract][Full Text] [Related]
14. Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls. Darras BT; Masson R; Mazurkiewicz-Bełdzińska M; Rose K; Xiong H; Zanoteli E; Baranello G; Bruno C; Vlodavets D; Wang Y; El-Khairi M; Gerber M; Gorni K; Khwaja O; Kletzl H; Scalco RS; Fontoura P; Servais L; N Engl J Med; 2021 Jul; 385(5):427-435. PubMed ID: 34320287 [TBL] [Abstract][Full Text] [Related]
15. The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Glanzman AM; Mazzone E; Main M; Pelliccioni M; Wood J; Swoboda KJ; Scott C; Pane M; Messina S; Bertini E; Mercuri E; Finkel RS Neuromuscul Disord; 2010 Mar; 20(3):155-61. PubMed ID: 20074952 [TBL] [Abstract][Full Text] [Related]